Takeda Pharmaceutical Statistics Share Statistics Takeda Pharmaceutical has 3.16B
shares outstanding. The number of shares has increased by -0.25%
in one year.
Shares Outstanding 3.16B Shares Change (YoY) -0.25% Shares Change (QoQ) -0.73% Owned by Institutions (%) 4.49% Shares Floating 3.16B Failed to Deliver (FTD) Shares 1,021 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 4.53M, so 0.14% of the outstanding
shares have been sold short.
Short Interest 4.53M Short % of Shares Out 0.14% Short % of Float 0.14% Short Ratio (days to cover) 1.67
Valuation Ratios The PE ratio is 66.33 and the forward
PE ratio is 0.33.
Takeda Pharmaceutical's PEG ratio is
-2.57.
PE Ratio 66.33 Forward PE 0.33 PS Ratio 1.56 Forward PS 0 PB Ratio 1.03 P/FCF Ratio 8.36 PEG Ratio -2.57
Financial Ratio History Enterprise Valuation Takeda Pharmaceutical has an Enterprise Value (EV) of 8,260.6B.
EV / Sales 1.8 EV / EBITDA 6.82 EV / EBIT 7.81 EV / FCF 9.65
Financial Position The company has a current ratio of 1.01,
with a Debt / Equity ratio of 0.73.
Current Ratio 1.01 Quick Ratio 0.52 Debt / Equity 0.73 Debt / EBITDA 4.19 Debt / FCF 5.92 Interest Coverage 0
Financial Efficiency Return on Equity is 1.56% and Return on Invested Capital is 1.72%.
Return on Equity 1.56% Return on Assets 0.76% Return on Invested Capital 1.72% Revenue Per Employee $92.97M Profits Per Employee $2.19M Employee Count 49,281 Asset Turnover 0.32 Inventory Turnover 1.3
Taxes Income Tax 66.94B Effective Tax Rate 38.23%
Stock Price Statistics The stock price has increased by 4.19% in the
last 52 weeks. The beta is 0.27, so Takeda Pharmaceutical's
price volatility has been higher than the market average.
Beta 0.27 52-Week Price Change 4.19% 50-Day Moving Average 14.8 200-Day Moving Average 14.23 Relative Strength Index (RSI) 48.9 Average Volume (20 Days) 3,276,508
Income Statement In the last 12 months, Takeda Pharmaceutical had revenue of 4,581.6B
and earned 107.93B
in profits. Earnings per share was 34.17.
Revenue 4,581.6B Gross Profit 3,001.3B Operating Income 342.59B Net Income 107.93B EBITDA 1,210.5B EBIT 449.12B Earnings Per Share (EPS) 34.17
Full Income Statement Balance Sheet The company has 385.11B in cash and 5,066.2B in
debt, giving a net cash position of -4,681.1B.
Cash & Cash Equivalents 385.11B Total Debt 5,066.2B Net Cash -4,681.1B Retained Earnings 1,187.6B Total Assets 14,248.3B Working Capital 14.67B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 1,057.2B
and capital expenditures -200.79B, giving a free cash flow of 856.39B.
Operating Cash Flow 1,057.2B Capital Expenditures -200.79B Free Cash Flow 856.39B FCF Per Share 266.73
Full Cash Flow Statement Margins Gross margin is 65.51%, with operating and profit margins of 7.48% and 2.36%.
Gross Margin 65.51% Operating Margin 7.48% Pretax Margin 3.82% Profit Margin 2.36% EBITDA Margin 26.42% EBIT Margin 7.48% FCF Margin 18.69%
